Literature DB >> 29104103

Dose ranging effects of vitamin D3 on the geriatric depression score: A clinical trial.

Vinod Yalamanchili1, J Christopher Gallagher2.   

Abstract

Depression is a common problem affecting millions, usually treated with selective serotonin uptake inhibitors. Interest in vitamin D as a co-therapy was stimulated by some association studies that correlated depression with low serum 25OHD levels. There are few longitudinal studies of vitamin D and depression and most are single doses of vitamin D. In this study we examined the effect of one-year treatment with several doses of vitamin D on the Geriatric depression score (GDS) in older Caucasian and African American women. The clinical trial was a study of seven daily oral doses of vitamin D (400-4800IU/d) in Black and White older women. The trial was a double blind, randomized and placebo controlled lasting 12-months. The main inclusion criterion was serum 25 hydroxyvitamin D (25OHD)≤20ng/mL (50nmol/L). Calcium supplements were given to maintain calcium intake 1000mg/day in young people and 1200-1400mg/day in older women. Data on Geriatric depression (GDS) was collected using the validated long form at baseline and 12-months. The change in serum 25OHD was the primary outcome and GDS was one of the secondary outcomes. Adjustments were made for relevant covariates. Analysis of vitamin D effect was by dose low, medium and high compared to placebo or by quintiles. Serum 25OHD increased as a quadratic curve function to a mean of 46ng/mL (115nmol/L) in white women and 49ng/mL (122.5nmol/L) in black women on the highest dose of 4800 IU. In older women mean GDS scores changed from 3.8 (SD±4.2) at baseline to 3.6 (SD±4.1) at 12 months in whites and from 3.0 (SD±3.7) to 3.02 (SD±4.2) in Blacks. (p=0.790 in whites; p=0.958 in blacks). After 12-months there was no effect of dose on change in GDS score in women treated with different doses of vitamin D (p=0.507 in whites and p=0.340 in blacks). When both Caucasians and African Americans were divided into 3 dose groups, low (400-800 IU), medium (1600-3200 IU) and high (4000-4800 IU) doses, the change in score was 0.8 on low dose, -0.30 on medium dose and -0.31 on high dose compared to 0.11 on placebo (p=0.546). In summary, there was no improvement in GDS scores in Caucasians or African Americans on either increasing doses of vitamin D or quintiles of achieved response in serum 25OHD. The changes were small and not significant perhaps because of the relatively lower numbers of depressed women in the groups. Further studies should recruit larger numbers, 3 dose groups covering a serum25OHD range of 20-60ng/mL and more subjects with clinical depression in order to fully address the question of vitamin D effects on depression.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Depression; Elderly; Vitamin D insufficiency; Vitamin D3; White and black women

Mesh:

Substances:

Year:  2017        PMID: 29104103      PMCID: PMC5854154          DOI: 10.1016/j.jsbmb.2017.10.025

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  29 in total

1.  No associations between serum concentrations of 25-hydroxyvitamin D and parathyroid hormone and depression among US adults.

Authors:  Guixiang Zhao; Earl S Ford; Chaoyang Li; Lina S Balluz
Journal:  Br J Nutr       Date:  2010-07-20       Impact factor: 3.718

2.  Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study.

Authors:  MinhTu T Hoang; Laura F Defina; Benjamin L Willis; David S Leonard; Myron F Weiner; E Sherwood Brown
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

3.  Association of vitamin D levels with incident depression among a general cardiovascular population.

Authors:  Heidi T May; Tami L Bair; Donald L Lappé; Jeffrey L Anderson; Benjamin D Horne; John F Carlquist; Joseph B Muhlestein
Journal:  Am Heart J       Date:  2010-06       Impact factor: 4.749

4.  Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine.

Authors:  Wayne A Cass; Michael P Smith; Laura E Peters
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

5.  Possible role of nitric oxide and adrenomedullin in bipolar affective disorder.

Authors:  Haluk A Savaş; Hasan Herken; Muhittin Yürekli; Efkan Uz; Hamdi Tutkun; Süleyman Salih Zoroğlu; Murat Eren Ozen; Beyhan Cengiz; Omer Akyol
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

6.  Serum vitamin D concentrations are related to depression in young adult US population: the Third National Health and Nutrition Examination Survey.

Authors:  Vijay Ganji; Cristiana Milone; Mildred M Cody; Frances McCarty; Yong T Wang
Journal:  Int Arch Med       Date:  2010-11-11

Review 7.  The molecular neurobiology of depression.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

8.  Seasonal mood changes in 250 normal women.

Authors:  S Harris; B Dawson-Hughes
Journal:  Psychiatry Res       Date:  1993-10       Impact factor: 3.222

9.  Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women.

Authors:  J C Dumville; J N V Miles; J Porthouse; S Cockayne; L Saxon; C King
Journal:  J Nutr Health Aging       Date:  2006 Mar-Apr       Impact factor: 4.075

10.  Association between depressive symptoms and 25-hydroxyvitamin D in middle-aged and elderly Chinese.

Authors:  An Pan; Ling Lu; Oscar H Franco; Zhijie Yu; Huaixing Li; Xu Lin
Journal:  J Affect Disord       Date:  2009-02-27       Impact factor: 4.839

View more
  1 in total

1.  Effects of vitamin D on insulin resistance and fasting blood glucose in pregnant women with insufficient or deficient vitamin D: a randomized, placebo-controlled trial.

Authors:  Zahra Mirzaei-Azandaryani; Sakineh Mohammad-Alizadeh-Charandabi; Elnaz Shaseb; Shamsi Abbasalizadeh; Mojgan Mirghafourvand
Journal:  BMC Endocr Disord       Date:  2022-10-20       Impact factor: 3.263

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.